Next-generation sequencing (NGS) allows high-throughput detection of molecular changes in tumors. Over the past 15 years, NGS has rapidly evolved from a promising research tool to a core component of the clinical laboratory. Sequencing of tumor cells provides an important step in detecting somatic driver mutations that not only characterize the disease but also influence treatment decisions. For patients with hematologic malignancies, NGS has been used for accurate classification and diagnosis based on genetic alterations. The recently revised World Health Organization classification and the European LeukemiaNet recommendations for acute myeloid leukemia consider genetic abnormalities as a top priority for diagnosis, prognostication, monitoring of measurable residual disease, and treatment choice. This review aims to present the role and utility of various NGS approaches for the diagnosis, treatment, and follow-up of hemato-oncology patients.
6 December 2017 in The American Journal of Tropical Medicine and Hygiene
We report the first isolation of Anaplasma phagocytophilum in South Korea. A 61-year-old woman presented with a 6-day history of fever, headache, and myalgia. Initial investigation showed neutropenia and thrombocytopenia. We diagnosed human granulocytic anaplasmosis by microscopic examination and serologic testing. The patient recovered fully without antibiotic therapy. The isolate was obtained from the patient’s blood by cell culture and mouse inoculation. Its identity was confirmed by an immunofluorescence assay, sequencing of the 16S rRNA gene, msp2 (p44), and ankA genes, and staining and electron microscopy of morulae of A. phagocytophilum in cultured human promyelocytic leukemia HL-60 cells.
1 January 2015 in Journal of Korean Medical Science
Background: We analyzed expression profiles of immune checkpoint receptors on T cell subsets and ligands on leukemic blasts in patients with B‐lymphoblastic leukemia (B‐ALL).Methods: Total 149 bone marrow (BM) samples obtained from 65 B‐ALL patients with four different clinical status (41 at diagnosis, 54 in complete remission [CR], 34 in persistence, and 20 in relapse), and 32 BM control samples were prospectively enrolled. Expression of immune checkpoint receptor (programmed cell death protein‐1 [PD‐1]) on T cell subsets and ligands (PD‐L1, PD‐L2) on leukemic blasts was evaluated by flow cytometry, and was compared between patient subgroups.Results: Relapsed patients demonstrated highest PD‐1 expression proportion and intensity on CD3+CD4+ T cells with statistical significance when compared to patients in persistence/CR/BM controls (p = .027/<.001/<.001 and .012/.001/<.001, respectively). Newly diagnosed patients showed significantly lower PD‐1 expression proportion on CD3+CD4+ T cells than relapsed patients (p < .001), but their intensity was not significantly different. Relapsed patients showed significantly higher PD‐1 expression proportion and intensity on CD3+CD8+ T cells than patients in CR/BM controls (p = .022/.045 and .049/.005, respectively), but PD‐1 expression status on them were not significantly different between relapsed and newly diagnosed patients. PD‐L1/L2 expression on leukemic blasts was not significantly different between patient subgroups.Conclusions: In BM aspirates from B‐ALL patients, PD‐1 expression on T‐cell subsets is increased at diagnosis, and to a greater extent, at relapse. These data suggest the potential usefulness of PD‐1 blockade in the treatment of B‐ALL, particularly at relapse.